Show simple item record

dc.contributor.authorHacioglu, Sibel
dc.contributor.authorBilen, Yusuf
dc.contributor.authorEser, Ali
dc.contributor.authorSivgin, Serdar
dc.contributor.authorGurkan, Emel
dc.contributor.authorYildirim, Rahsan
dc.contributor.authorAydogdu, Ismet
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorKayikci, Omur
dc.contributor.authorTombak, Anil
dc.contributor.authorKuku, Irfan
dc.contributor.authorCelebi, Harika
dc.contributor.authorAkay, Meltem Olga
dc.contributor.authorEsen, Ramazan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorKeskin, Ali
dc.descriptionWOS: 000368248400011en_US
dc.descriptionPubMed ID: 25393847en_US
dc.description.abstractIn this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd.en_US
dc.subjecthairy cell leukemiaen_US
dc.titleMulticenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapyen_US
dc.relation.journalHEMATOLOGICAL ONCOLOGYen_US
dc.contributor.department[Hacioglu, Sibel -- Dogu, Mehmet Hilmi -- Keskin, Ali] Pamukkale Univ, Dept Hematol, TR-20070 Denizli, Turkey -- [Bilen, Yusuf -- Yildirim, Rahsan] Ataturk Univ, Dept Hematol, Erzurum, Turkey -- [Eser, Ali] Marmara Univ, Dept Hematol, Istanbul, Turkey -- [Sivgin, Serdar] Erciyes Univ, Dept Hematol, Kayseri, Turkey -- [Gurkan, Emel] Cukurova Univ, Dept Hematol, Adana, Turkey -- [Aydogdu, Ismet] Celal Bayar Univ, Dept Hematol, Manisa, Turkey -- [Yilmaz, Mehmet] Gaziantep Univ, Dept Hematol, Gaziantep, Turkey -- [Kayikci, Omur] Ankara Oncol Educ & Res Hosp, Dept Hematol, Ankara, Turkey -- [Tombak, Anil] Mersin Univ, Dept Hematol, Mersin, Turkey -- [Kuku, Irfan] Inonu Univ, Dept Hematol, Malatya, Turkey -- [Celebi, Harika] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Hematol, Ankara, Turkey -- [Akay, Meltem Olga] Osmangazi Univ, Dept Hematol, Eskisehir, Turkey -- [Esen, Ramazan] Yuzuncu Yil Univ, Dept Hematol, Van, Turkey -- [Korkmaz, Serdal] Cumhuriyet Univ, Dept Hematol, Sivas, Turkeyen_US
dc.contributor.authorIDGURKAN, EMEL -- 0000-0002-3060-4054en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record